Share Twitter LinkedIn Facebook Email Pascal Besman Chief Operating Officer at PharmaMar discusses IO Likely In 1st Line SCLC. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.
Lurbinectedin: Enhancing Immunotherapy Efficacy in Small Cell Lung Cancer Small Cell Lung Cancer 3 Mins Read
HARPOON THERAPEUTICS: New data on HPN328 T cell engager at ESMO 2023 Small Cell Lung Cancer 2 Mins Read
Emerging Treatment for SCLC – Leading Developments & Current Questions in Lung Cancer Small Cell Lung Cancer 1 Min Read